Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder.

Meridian Medical Technologies, a Pfizer subsidiary, and Teva have entered into a settlement agreement to resolve generic epinephrine auto-injector pending patent litigation.

Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

Watson Pharmaceuticals has introduced an authorized generic version of Fortamet as a part of an agreement with Shionogi.

Elis Pharmaceuticals will present erectile dysfunction drug Vitaros licensed from Apricus Biosciences at the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT), as part of its pre-launch strategy.

EyeScience Labs, a resource in ocular nutrition and maker of EyeScience Macular Health Formula and EyeScience Dry Eye Formula, has developed a new eye vitamin for people with diabetes.

APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received FDA approval to market preservative-free Methotrexate Injection, USP.

Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia.

La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics.

The global law firm, Morrison & Foerster has advised Novartis to sign an exclusive collaboration, option and license agreement with Camurus, a Swedish research-based pharmaceutical company.